Nkarta, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nkarta, Inc..The latest application filed is for "combinations of engineered natural killer cells and engineered t cells for immunotherapy".

Company Profile

4.8.8

Nkarta, Inc. - South San Francisco CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Combinations Of Engineered Natural Killer Cells And Engineered T Cells For Immunotherapy App 20220233593 - Trager; James Barnaby ; et al.	2022-07-28
Cd19-directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy App 20220233590 - TRAGER; James Barnaby ; et al.	2022-07-28
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy Grant 11,365,236 - Leong , et al. June 21, 2	2022-06-21
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Grant 11,253,547 - Trager , et al. February 22, 2	2022-02-22
Methods For The Simultaneous Expansion Of Multiple Immune Cell Types, Related Compositions And Uses Of Same In Cancer Immunotherapy App 20220047635 - LIU; Daofeng ; et al.	2022-02-17
Genetically Modified Natural Killer Cells For Cd70-directed Cancer Immunotherapy App 20220002424 - Trager; James Barnaby ; et al.	2022-01-06
Natural Killer Cell Compositions And Immunotherapy Methods For Treating Tumors App 20210338727 - TRAGER; James Barnaby ; et al.	2021-11-04
Cancer immunotherapy using CD19-directed chimeric antigen receptors Grant 11,154,575 - Trager , et al. October 26, 2	2021-10-26
Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Grant 11,141,436 - Trager , et al. October 12, 2	2021-10-12
Immune Cells Engineered To Express Cd19-directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy App 20210070857 - Trager; James Barnaby ; et al.	2021-03-11
Cd19-directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy App 20210070856 - Trager; James Barnaby ; et al.	2021-03-11
Cancer Immunotherapy Using Cd19-directed Chimeric Antigen Receptors App 20210060073 - Trager; James Barnaby ; et al.	2021-03-04
Truncated NKG2D Chimeric Receptors And Uses Thereof In Natural Killer Cell Immunotherapy App 20200131244A1 -	2020-04-30

Company Registrations

SEC

0001787400

Nkarta, Inc. of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.